Insight Tribune

Novo Nordisk Shares Surge on New Obesity Drug Results

Novo Nordisk Shares Surge on New Obesity Drug Results




Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial.

Exit mobile version